Lexaria Bioscience (LEXX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Lexaria Bioscience (LEXX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.49 Mn |
1.97 Mn |
20,000.00 |
2.50% |
| Date | Value |
|---|
| Feb 28, 2026 |
2.50% |
| Nov 30, 2025 |
-3.85% |
| Aug 31, 2025 |
56.59% |
| May 31, 2025 |
53.19% |
| Feb 28, 2025 |
23.72% |
| Nov 30, 2024 |
49.70% |
| Aug 31, 2024 |
56.97% |
| May 31, 2024 |
39.32% |
| Feb 29, 2024 |
51.61% |
| Nov 30, 2023 |
55.00% |
| Aug 31, 2023 |
54.37% |
| May 31, 2023 |
55.54% |
| Feb 28, 2023 |
49.90% |
| Nov 30, 2022 |
58.53% |
| Aug 31, 2022 |
-10.82% |
| May 31, 2022 |
-26.69% |
| Feb 28, 2022 |
48.00% |
| Nov 30, 2021 |
-41.64% |
| Aug 31, 2021 |
1.35% |
| May 31, 2021 |
9.28% |
